MoonLake Immunotherapeutics Investor Relations Material
Latest events
CMD 2025
MoonLake Immunotherapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from MoonLake Immunotherapeutics
Access all reports
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company, focusing on the development of innovative therapies for inflammatory diseases. The company is advancing Sonelokimab, a novel investigational Nanobody, to address conditions such as hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and axial spondyloarthritis. MoonLake Immunotherapeutics aims to leverage the therapeutic potential of Sonelokimab to meet significant unmet medical needs in the treatment of these diseases. MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, and its shares are listed on the NASDAQ.
Key slides for MoonLake Immunotherapeutics
CMD 2025
MoonLake Immunotherapeutics
CMD 2024
MoonLake Immunotherapeutics
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
MLTX
Country
🇺🇸 United States